Cancer
Lung cancer in Beijing
北京 肺癌
20 hospitals in Beijing
Order: papers led on lung cancer, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for lung cancer: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Beijing may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 587 papers led
- 213 papers led
- 176 papers ledNo open trial led
- 161 papers led
- 102 papers led
- 80 papers led
- 74 papers ledNo open trial led
- 66 papers led
- 56 papers led
- 53 papers led
- 51 papers led
- 47 papers ledNo open trial led
- 38 papers ledNo open trial led
- 34 papers ledNo open trial led
- 32 papers ledNo open trial led
- 32 papers led
- 26 papers led
- 18 papers ledNo open trial led
- 9 papers ledNo open trial led
- 0 papers led
Lung cancer in every city Beijing on the disease page, with the national map
open trials on lung cancer with a hospital in Beijing
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Beijing as lead sponsor or study site. 95 of them are led by a hospital in Beijing. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- RecruitingThe Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
- Phase
- Not given
- Started
- 2026-09
- Posted
- Registry
- NCT07039474
Age 18 years to 75 years (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingA Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Phase
- Phase 2/Phase 3
- Started
- 2026-01
- Posted
- Registry
- NCT07063745
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanning, Shanghai, Shenyang, Wuhan, Xiamen
- RecruitingA Study of DXC014 in Patients With Advanced Solid Tumors.
- Phase
- Phase 1
- Started
- 2026-03
- Posted
- Registry
- NCT07177937
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Nanchang, Qingdao
- RecruitingBeamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Phase
- Phase 3
- Started
- 2026-01
- Posted
- Registry
- NCT07195695
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Shijiazhuang, Suzhou, Taizhou, Tianjin, Wuhan, Xuzhou, Yangzhou, Zhengzhou
- RecruitingSymbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2026-01
- Posted
- Registry
- NCT07222566
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jiangmen, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou
- RecruitingSymbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07227298
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Fuzhou, Nanjing, Shanghai, Taizhou, Wuhan
- RecruitingA Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07227597
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jiangmen, Nanchang, Shanghai, Taizhou
- RecruitingThis Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.
- Phase
- Phase 1
- Started
- 2026-03
- Posted
- Registry
- NCT07249879
Age 18 years to 75 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingStudy to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07288177
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Nanjing, Shanghai, Tianjin, Zhengzhou
- RecruitingPhase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07329322
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingFirst-in-Human Expanded Cohort Study of Intrapleural Administration of TolueneSulfonamide in Patients With Malignant Pleural Effusion
- Phase
- Phase 1/Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07332858
Age 18 years to 75 years (registered criteria)
Led by China-Japan Friendship HospitalBeijing
- RecruitingA First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07354711
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07361497
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Shantou, Shenzhen, Suzhou, Taiyuan, Taizhou, Xi'an, Zhengzhou
- RecruitingZorifertinib With Osimertinib for NSCLC With Meningeal Progression
- Phase
- Phase 1
- Started
- 2026-01
- Posted
- Registry
- NCT07361705
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Shenyang, Taiyuan, Zhengzhou
- RecruitingA Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
- Phase
- Phase 1/Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07367529
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Yangzhou, Zhongshan
- RecruitingYSQTG Combined With Immuno-chemotherapy for Extensive-Stage Small Cell Lung Cancer
- Phase
- N/A
- Started
- 2026-12
- Posted
- Registry
- NCT07390565
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingA Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment
- Phase
- Phase 1
- Started
- 2026-01
- Posted
- Registry
- NCT07413042
Age 18 years to 80 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingRC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
- Phase
- Phase 3
- Started
- 2026-04
- Posted
- Registry
- NCT07416474
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 66 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Urumqi, Wenzhou, Wuhan, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yantai, Yinchuan, Zhengzhou, Zhuhai
- RecruitingA Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC
- Phase
- Phase 1
- Started
- 2026-04
- Posted
- Registry
- NCT07416695
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai
- RecruitingMK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07431827
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanchang, Nanning, Shanghai, Shijiazhuang, Urumqi, Wuhan
- RecruitingAn Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC
- Phase
- N/A
- Started
- 2026-01
- Posted
- Registry
- NCT07452003
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingA Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07459751
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingDAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Phase
- Phase 3
- Started
- 2026-04
- Posted
- Registry
- NCT07472517
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Xuzhou, Yangzhou, Zhengzhou
- RecruitingSymbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07476287
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Hangzhou, Nanchang, Shanghai, Wuhan, Zhengzhou
- RecruitingA Retrospective Real-World Study Based on RATIONALE-307
- Phase
- Not given
- Started
- 2026-02
- Posted
- Registry
- NCT07478809
Age not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingCadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors
- Phase
- Not given
- Started
- 2026-03
- Posted
- Registry
- NCT07487883
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingSymbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07489066
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai
- RecruitingFulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07492342
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou
- RecruitingA Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07541170
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Changchun, Chengdu, Foshan, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Shenzhen, Suzhou, Taizhou, Tianjin
- RecruitingA Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
- Phase
- Phase 3
- Started
- 2026-06
- Posted
- Registry
- NCT07554339
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanjing, Nanning, Shanghai, Shijiazhuang, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Xiamen
- Recruiting18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
- Phase
- N/A
- Started
- 2026-04
- Posted
- Registry
- NCT07557225
Age 18 years to Not stated (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingA Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07586202
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin
- RecruitingA Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07622186
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Jinan, Kunming, Nanchang, Nanjing, Nanning, Shenyang, Taiyuan, Tianjin, Xi'an, Xiamen, Xiangyang, Zhengzhou
- RecruitingFirmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07622706
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingCharacterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy
- Phase
- Not given
- Started
- 2026-05
- Posted
- Registry
- NCT07668037
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingLabel-free Femtosecond Laser Imaging Combined With the Fast Lung Artificial Intelligence Model for Rapid Intraoperative Diagnosis of Lung Surgical Specimens: A Multicentre, Prospective, Parallel-workflow, Non-inferiority Study.
- Phase
- Not given
- Started
- 2026-07
- Posted
- Registry
- NCT07681245
Age 18 years to 90 years (registered criteria)
Led by Shanghai Chest Hospital; 3 listed hospitals as study sitesBeijing, Shanghai
- RecruitingA Study of DS-3939a in Participants With Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07739966
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changchun, Changsha, Guangzhou, Hangzhou, Harbin, Jinan, Shanghai, Taizhou, Tianjin, Wuhan, Zhengzhou
- Recruiting68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
- Phase
- N/A
- Started
- 2026-08
- Posted
- Registry
- NCT07760012
Age 18 years to Not stated (registered criteria)
Led by Peking University Third HospitalBeijing
- RecruitingPhase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
- Phase
- Phase 3
- Started
- 2026-08
- Posted
- Registry
- NCT07778316
Age 18 years to 99 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai
- RecruitingReal World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung Cancer
- Phase
- Not given
- Started
- 2026-09
- Posted
- Registry
- NCT07806604
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai
- RecruitingClinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07848243
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingMRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer
- Phase
- N/A
- Started
- 2026-08
- Posted
- Registry
- NCT07894458
Age 18 years to 85 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingNectin-4 Specific LMW PET Probe Imaging in Multiple Solid Tumors
- Phase
- N/A
- Started
- 2025-05
- Posted
- Registry
- NCT05321316
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingA Study on the Improvement of Postoperative Symptoms and Survival Benefits of Modified Bufei Decoction in Elderly Patients With Lung Cancer Undergoing Radical Surgery
- Phase
- N/A
- Started
- 2025-06
- Posted
- Registry
- NCT06674252
Age 65 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingSafety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- Phase
- Phase 2/Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT06712316
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chongqing, Hangzhou, Jinan, Shanghai, Shantou, Shijiazhuang, Suzhou, Taizhou, Wuhan, Yangzhou
- RecruitingSafety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-02
- Posted
- Registry
- NCT06712355
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Shanghai, Shantou, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou
- RecruitingThis is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT06758401
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taizhou, Tianjin, Wenzhou, Wuhan, Xi'an, Xuzhou, Zhengzhou
- RecruitingAssessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06768307
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingSubstudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
- Phase
- Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06780098
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Chongqing, Fuzhou, Nanjing, Nanning, Shanghai, Zhengzhou
- RecruitingA Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
- Phase
- Phase 1/Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06780137
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Nanjing, Shanghai
- RecruitingA Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-02
- Posted
- Registry
- NCT06792552
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Jinan, Shanghai, Shenyang, Shijiazhuang
- RecruitingA Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT06793215
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nantong, Shanghai, Shantou, Wuhan
- RecruitingStudy of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-04
- Posted
- Registry
- NCT06801834
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanjing, Shanghai, Shenzhen, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xinxiang, Yangzhou, Zhengzhou
- RecruitingClinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
- Phase
- Not given
- Started
- 2025-02
- Posted
- Registry
- NCT06809764
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 30 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Wuhan, Xiamen, Zhengzhou
- RecruitingA Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs
- Phase
- Phase 3
- Started
- 2025-04
- Posted
- Registry
- NCT06829459
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingImmunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCLC
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06849167
Age 18 years to 70 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingA Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT06855771
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Hangzhou, Jinan, Linyi, Nanchang, Nanning, Taizhou, Xiamen
- RecruitingThe Purpose of This Study is to Evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Monotherapy in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC)
- Phase
- Phase 1
- Started
- 2025-03
- Posted
- Registry
- NCT06861543
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingReal World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
- Phase
- Not given
- Started
- 2025-04
- Posted
- Registry
- NCT06862869
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Lanzhou, Nanchang, Nanjing, Nantong, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Wuhan, Wuxi, Xi'an, Yinchuan, Zhanjiang, Zunyi
- RecruitingPrediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy
- Phase
- Not given
- Started
- 2025-02
- Posted
- Registry
- NCT06869239
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Phase
- Phase 3
- Started
- 2025-04
- Posted
- Registry
- NCT06875310
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou
- RecruitingStudy of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06890598
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesAnyang, Beijing, Changsha, Chengdu, Chongqing, Foshan, Guangzhou, Hangzhou, Harbin, Jinan, Luoyang, Nanning, Shanghai, Shantou, Shenzhen, Suzhou, Taizhou, Tianjin, Wuhan, Xi'an
- RecruitingA Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06892548
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Xi'an, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yichang, Zhengzhou
- RecruitingStudy of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06895031
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingPerioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT06897046
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT06899126
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xiangyang, Zhengzhou
- RecruitingSafety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-05
- Posted
- Registry
- NCT06902350
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Changchun
- RecruitingA Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT06907615
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingAcupuncture Combined With PD-1/PD-L1 Inhibitors for Advanced Lung Cancer
- Phase
- N/A
- Started
- 2025-06
- Posted
- Registry
- NCT06926140
Age 18 years to 75 years (registered criteria)
Led by Guang'anmen Hospital; 1 listed hospital as study siteBeijing, Hefei
- RecruitingA Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT06930794
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Guangzhou
- RecruitingLiquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer
- Phase
- N/A
- Started
- 2025-03
- Posted
- Registry
- NCT06930807
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingA Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT06962865
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Jinan, Kunming, Linyi, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Yantai, Zhengzhou
- RecruitingA Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC
- Phase
- Phase 1
- Started
- 2025-05
- Posted
- Registry
- NCT06969612
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingA Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT07010263
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Harbin, Jiangmen, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xinxiang, Yinchuan, Zhengzhou, Zunyi
- RecruitingConsolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-Immunotherapy
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07014202
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingA Study of SKB518 in Patients With Lung Cancer
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07019675
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shanghai, Shenzhen, Taiyuan, Taizhou, Tianjin, Urumqi, Wuhan, Xiangyang, Zhengzhou
- RecruitingA Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung Cancer
- Phase
- Not given
- Started
- 2025-01
- Posted
- Registry
- NCT07026669
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingMultiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung Cancer
- Phase
- Not given
- Started
- 2025-01
- Posted
- Registry
- NCT07057102
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingSpatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07058948
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & Hospital; 1 listed hospital as study siteBeijing, Tianjin
- RecruitingStudy of GV20-0251 in Participants With Solid Tumor Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07070518
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai
- RecruitingStudy of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07079475
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanjing, Shanghai, Shenyang, Tianjin
- RecruitingPhase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT07087223
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer Hospital; 7 listed hospitals as study sitesBeijing, Dalian, Shijiazhuang, Tianjin
- RecruitingGolidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07110103
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMS; 1 listed hospital as study siteBeijing, Chongqing
- RecruitingStudy to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07120282
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingA Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07144280
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Taizhou, Wuhan, Xi'an, Xuzhou, Zhengzhou
- RecruitingPhase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
- Phase
- Phase 3
- Started
- 2025-08
- Posted
- Registry
- NCT07154706
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Jinan, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingA Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07164170
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Nanjing, Nanning, Shanghai, Shenyang, Wuhan, Xi'an, Zhengzhou
- RecruitingEfficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer
- Phase
- Not given
- Started
- 2025-04
- Posted
- Registry
- NCT07166003
Age 18 years to 79 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingA Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07174908
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai, Wuhan, Zhengzhou
- RecruitingA Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07182682
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 47 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xuzhou, Zhengzhou
- RecruitingStudy to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07185997
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xinxiang, Zhengzhou
- RecruitingA Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- Phase
- Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT07190248
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingIBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07198841
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Foshan, Guangzhou, Nanchang, Nanning, Shijiazhuang
- RecruitingA Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-11
- Posted
- Registry
- NCT07217301
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luzhou, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Xi'an, Xinxiang, Xuzhou, Zhengzhou
- RecruitingA Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
- Phase
- Phase 3
- Started
- 2025-11
- Posted
- Registry
- NCT07218146
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingA Study of Ivonescimab in First-Line ES-SCLC
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07245446
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai, Xi'an
- RecruitingApplication of Methylation Markers in Early Detection and MRD Monitoring of Lung Cancer
- Phase
- Not given
- Started
- 2025-04
- Posted
- Registry
- NCT07257458
Age 18 years to 85 years (registered criteria)
Led by Beijing Haidian HospitalBeijing
- RecruitingApplication Research of Methylation Markers in Early-stage Lung Cancer Patients Treated With Co-ablation System Therapy
- Phase
- Not given
- Started
- 2025-06
- Posted
- Registry
- NCT07257471
Age 18 years to 85 years (registered criteria)
Led by Beijing Haidian HospitalBeijing
- RecruitingTo Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)
- Phase
- Not given
- Started
- 2025-05
- Posted
- Registry
- NCT07291921
Age 18 years to 85 years (registered criteria)
Led by Peking University People's HospitalBeijing
- Recruiting68Ga-PFA2 PET Imaging for the Diagnosis of Annexin A2-Positive Tumors
- Phase
- Not given
- Started
- 2025-06
- Posted
- Registry
- NCT07331532
Age 18 years to 80 years (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingMechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
- Phase
- Not given
- Started
- 2025-07
- Posted
- Registry
- NCT07359040
Age not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingA Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib
- Phase
- Phase 1/Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07362940
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Changsha, Jinan, Xiamen, Zhengzhou
- RecruitingAn Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07371663
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou, Zhengzhou
- RecruitingAnlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.
- Phase
- Phase 3
- Started
- 2025-08
- Posted
- Registry
- NCT07443397
Age 18 years to 80 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingFAP-targeted PET/NIR in Lung Malignant Tumors
- Phase
- Not given
- Started
- 2025-06
- Posted
- Registry
- NCT07498933
Age 18 years to 70 years (registered criteria)
Led by Peking University People's HospitalBeijing
- Recruiting68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07508852
Age 18 years to Not stated (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingRomiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07586826
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingStudy of LY01610 in Patients With Recurrent Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2024-03
- Posted
- Registry
- NCT06128837
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Study of ZL-1310 in Subjects With Small Cell Lung Cancer
- Phase
- Phase 1
- Started
- 2024-01
- Posted
- Registry
- NCT06179069
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Shanghai, Shenyang, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingA Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06203210
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Shanghai, Shenyang, Tianjin, Urumqi, Wuhan, Xiangyang, Yantai, Zhengzhou
- RecruitingSerplulimab Combined With CCRT for LS-SCLC.
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06295926
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingD-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
- Phase
- Phase 3
- Started
- 2024-03
- Posted
- Registry
- NCT06300177
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 63 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi
- RecruitingA Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Phase
- Phase 3
- Started
- 2024-04
- Posted
- Registry
- NCT06312137
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Suzhou, Taizhou, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06345729
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Suzhou, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Zhengzhou
- RecruitingICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06388031
Age 18 years to 80 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingJAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
- Phase
- Phase 3
- Started
- 2024-08
- Posted
- Registry
- NCT06416410
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Wuxi, Xi'an, Zhengzhou
- RecruitingA Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.
- Phase
- Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT06421298
Age 18 years to 75 years (registered criteria)
Led by Beijing Chest HospitalBeijing
- RecruitingPembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- Phase
- Phase 3
- Started
- 2024-06
- Posted
- Registry
- NCT06422143
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanchang, Shanghai, Taizhou, Urumqi, Wenzhou, Wuhan, Xiamen, Yangzhou, Zhengzhou
- RecruitingDose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.
- Phase
- Phase 1/Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06440057
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Phase
- Phase 3
- Started
- 2024-08
- Posted
- Registry
- NCT06452277
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanjing, Shanghai, Taizhou, Wuhan, Xiamen
- RecruitingA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Phase
- Phase 1
- Started
- 2024-07
- Posted
- Registry
- NCT06465069
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai
- RecruitingAdebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06467617
Age 18 years to 75 years (registered criteria)
Led by Beijing Chest HospitalBeijing
- RecruitingA Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06496490
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Harbin, Jiangmen, Nanchang, Nanning, Shanghai, Tianjin, Xi'an, Zhengzhou, Zunyi
- RecruitingA Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06512051
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingDifferentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath
- Phase
- Not given
- Started
- 2024-06
- Posted
- Registry
- NCT06518655
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Foshan, Guangzhou, Shanghai, Wuhan
- RecruitingA Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Phase
- Phase 3
- Started
- 2024-10
- Posted
- Registry
- NCT06561386
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Xinxiang
- RecruitingA Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
- Phase
- Phase 3
- Started
- 2024-11
- Posted
- Registry
- NCT06564324
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingA Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06581419
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingSafety and Efficacy of BA1302 in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2024-09
- Posted
- Registry
- NCT06596915
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingAblation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2024-10
- Posted
- Registry
- NCT06644430
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingRadiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions
- Phase
- Not given
- Started
- 2024-11
- Posted
- Registry
- NCT06648317
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingFurmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations
- Phase
- Phase 3
- Started
- 2024-07
- Posted
- Registry
- NCT06674343
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingThe Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy
- Phase
- Not given
- Started
- 2024-12
- Posted
- Registry
- NCT06692972
Age 18 years to Not stated (registered criteria)
Led by China-Japan Friendship Hospital; 1 listed hospital as study siteBeijing, Wuhan
- RecruitingAssessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)
- Phase
- Phase 1
- Started
- 2024-06
- Posted
- Registry
- NCT06813365
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingSafety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer
- Phase
- Not given
- Started
- 2024-12
- Posted
- Registry
- NCT06926179
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer Hospital; 2 listed hospitals as study sitesBeijing, Kunming
- RecruitingFirmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
- Phase
- Phase 3
- Started
- 2024-11
- Posted
- Registry
- NCT06956001
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Jinan
- RecruitingCarbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
- Phase
- Phase 1/Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT07433283
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Haikou, Harbin, Shanghai, Zhengzhou
- RecruitingClinical Study of a New Treatment Model for Elderly Lung Cancer Patients
- Phase
- N/A
- Started
- 2024-08
- Posted
- Registry
- NCT07632664
Age 65 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingPhase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2023-04
- Posted
- Registry
- NCT05786924
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Jinan, Shanghai, Suzhou
- RecruitingLK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2023-05
- Posted
- Registry
- NCT05886439
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingA Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2023-06
- Posted
- Registry
- NCT05913089
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Fuzhou, Shanghai, Taiyuan, Tianjin, Weifang
- RecruitingA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT05920356
Age 18 years to 100 years (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Weifang, Wuhan, Xi'an, Xiamen, Xiangyang, Zhengzhou
- RecruitingA Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
- Phase
- Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06010329
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Shanghai, Wuhan, Zhengzhou
- RecruitingPhase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT06095583
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Yinchuan, Zhengzhou
- RecruitingA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06119581
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Shanghai, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiangyang, Yichang, Zhanjiang
- RecruitingCOVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research
- Phase
- N/A
- Started
- 2023-12
- Posted
- Registry
- NCT06168032
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingSacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06170788
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Shanghai, Shijiazhuang, Taizhou, Wuhan, Wuxi, Xiamen, Xiangyang, Xuzhou, Zhanjiang, Zhengzhou
- RecruitingA Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Started
- 2022-03
- Posted
- Registry
- NCT04928846
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Zhanjiang, Zhengzhou
- RecruitingStudy to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2022-09
- Posted
- Registry
- NCT05168566
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Linyi, Nanjing, Shanghai, Shenyang, Wuhan, Zhengzhou
- RecruitingA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2022-10
- Posted
- Registry
- NCT05208762
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai
- RecruitingPhase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
- Phase
- Phase 1/Phase 2
- Started
- 2022-04
- Posted
- Registry
- NCT05288205
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Harbin, Hefei, Hohhot, Jinan, Linyi, Shanghai, Shenyang, Shenzhen, Wuhan, Xiamen, Zhengzhou
- RecruitingMultiomics Tumor Evolution Model of NSCLC
- Phase
- Not given
- Started
- 2022-04
- Posted
- Registry
- NCT05352035
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingJAB-2485 Activity in Adult Patients With Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2022-12
- Posted
- Registry
- NCT05490472
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Changchun, Jinan
- RecruitingA Real World Study of Ensartinib in Advanced ALK-positive NSCLC
- Phase
- Not given
- Started
- 2022-05
- Posted
- Registry
- NCT05498064
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingAdjuvant Treatment Based on MRD for EGFR Mutant NSCLC
- Phase
- Phase 2
- Started
- 2022-09
- Posted
- Registry
- NCT05536505
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou, Hefei, Qingdao, Shanghai, Shenzhen, Wuhan, Xiamen, Zhongshan
- RecruitingRinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Phase
- Phase 1/Phase 2
- Started
- 2022-12
- Posted
- Registry
- NCT05579366
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan
- RecruitingA Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation
- Phase
- Phase 1/Phase 2
- Started
- 2022-10
- Posted
- Registry
- NCT07231068
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Guangzhou, Zhengzhou
- RecruitingResearch on Early Screening and Diagnosis of Pulmonary Nodules Based on Novel Non-invasive Technologies.
- Phase
- Not given
- Started
- 2022-12
- Posted
- Registry
- NCT07370077
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingBeamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- Phase
- Phase 1
- Started
- 2021-07
- Posted
- Registry
- NCT04886804
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanning, Shanghai, Wuhan, Xiamen, Zhengzhou
- RecruitingStudy of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-09
- Posted
- Registry
- NCT04930432
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 56 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou
- RecruitingA Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-12
- Posted
- Registry
- NCT04996121
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingPhase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-11
- Posted
- Registry
- NCT05024214
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Shanghai, Shenyang, Taiyuan, Tianjin, Zhengzhou, Zhuhai
- RecruitingFirst in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
- Phase
- Phase 1/Phase 2
- Started
- 2021-10
- Posted
- Registry
- NCT05099172
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Hangzhou, Harbin, Jinan, Nanjing, Shanghai, Taizhou
- RecruitingA Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2021-10
- Posted
- Registry
- NCT05104788
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingAssessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)
- Phase
- N/A
- Started
- 2021-11
- Posted
- Registry
- NCT05559645
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingPhase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2021-12
- Posted
- Registry
- NCT05751018
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingIntraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery
- Phase
- N/A
- Started
- 2020-04
- Posted
- Registry
- NCT04209218
Age 50 years to 90 years (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingA Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
- Phase
- Phase 3
- Started
- 2020-07
- Posted
- Registry
- NCT04316364
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Nanjing, Shanghai, Zhengzhou
- RecruitingStudy to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- Phase
- Phase 2
- Started
- 2020-09
- Posted
- Registry
- NCT04557449
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Wuhan, Xi'an, Zhengzhou
- RecruitingStudy of PF-07248144 in Advanced or Metastatic Solid Tumors
- Phase
- Phase 2
- Started
- 2020-11
- Posted
- Registry
- NCT04606446
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Xi'an
- RecruitingPhase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Phase
- Phase 2/Phase 3
- Started
- 2020-12
- Posted
- Registry
- NCT04613596
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 30 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanning, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingAPG-2449 in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2019-05
- Posted
- Registry
- NCT03917043
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Wuhan
- RecruitingAssessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2019-07
- Posted
- Registry
- NCT04270591
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Zhengzhou
- RecruitingCharacteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
- Phase
- Not given
- Started
- 2019-11
- Posted
- Registry
- NCT06255197
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingDevelopment and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
- Phase
- Not given
- Started
- 2019-01
- Posted
- Registry
- NCT06950697
Age 18 years to Not stated (registered criteria)
Led by Beijing Chao-Yang Hospital; 2 listed hospitals as study sitesBeijing, Zhengzhou
- Not yet recruitingClinical Study on Fuzheng Jiedu Huayu Therapy in Combination With Chemotherapy and Immunotherapy for Improving Survival Rates in Extensive-Stage Small Cell Lung Cancer
- Phase
- N/A
- Started
- 2027-01
- Posted
- Registry
- NCT07928882
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingA Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07307443
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingA Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07338396
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Chengdu, Guangzhou
- Not yet recruitingExploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07357532
Age 18 years to 80 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingAdebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07381543
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingIBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07402070
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingOsimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib
- Phase
- Phase 1/Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07486648
Age 18 years to Not stated (registered criteria)
Led by Shanxi Cancer Hospital; 1 listed hospital as study siteBeijing, Taiyuan
- Not yet recruitingZorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07551414
Age 18 years to 75 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingAdebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07560358
Age 18 years to 75 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingA Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
- Phase
- Phase 1
- Started
- 2026-05
- Posted
- Registry
- NCT07583316
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruiting5T4 Targeting Nanobody Probe for PET Imaging in Solid Tumors
- Phase
- N/A
- Started
- 2026-06
- Posted
- Registry
- NCT07589101
Age 18 years to 70 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingIntermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07618793
Age 18 years to 75 years (registered criteria)
Led by Xuanwu HospitalBeijing
- Not yet recruitingA Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07623642
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Harbin
- Not yet recruitingDeep Learning Time-Series Prediction of Long-Term Growth Patterns of Pulmonary Ground-Glass Nodules Using Serial CT
- Phase
- Not given
- Started
- 2026-06
- Posted
- Registry
- NCT07647692
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- Not yet recruitingA Clinical Study GK01 Cell Injection in Subjects With Advanced Lung Cancer
- Phase
- Early phase 1
- Started
- 2026-07
- Posted
- Registry
- NCT07673419
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingVideo-Assisted Thoracoscopic Surgery Combined With Radiofrequency Ablation Versus VATS Alone for Multiple Primary Lung Cancer
- Phase
- N/A
- Started
- 2026-09
- Posted
- Registry
- NCT07819669
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shenzhen
- Not yet recruitingPhase 1 Study of ATRA Plus a PD-1 Inhibitor in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Resistance
- Phase
- Phase 1
- Started
- 2026-10
- Posted
- Registry
- NCT07842887
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingA Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2026-11
- Posted
- Registry
- NCT07865910
Age 18 days to 75 days (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesAnyang, Beijing, Chongqing, Guangzhou, Jinan, Nanning, Qingdao, Shijiazhuang, Wuhan, Xuzhou, Zhengzhou, Zunyi
- Not yet recruitingMRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLC
- Phase
- N/A
- Started
- 2026-11
- Posted
- Registry
- NCT07873086
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- Not yet recruitingDiagnostic Performance of an AI-Based Multi-Omics Model for Early Lung Cancer
- Phase
- Not given
- Started
- 2026-10
- Posted
- Registry
- NCT07882628
Age 18 years to 75 years (registered criteria)
Led by Beijing Chao-Yang Hospital; 4 listed hospitals as study sitesBeijing, Changsha
- Not yet recruitingMRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC
- Phase
- Phase 2
- Started
- 2026-11
- Posted
- Registry
- NCT07885709
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- Not yet recruitingThe Diagnostic Value of Bronchoscopic Needle-based Confocal Laser Endomicroscopy (nCLE) As a Real-time Detection Tool for Diagnosing Peripheral Lung Cancer: a Multi-centre Randomised Controlled Trial
- Phase
- N/A
- Started
- 2025-01
- Posted
- Registry
- NCT06739421
Age 18 years to 90 years (registered criteria)
Led by China-Japan Friendship HospitalBeijing
- Not yet recruitingAdjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06780839
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingAdebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limited-Stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06784206
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingStudy of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06885840
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Foshan, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Shenyang, Tianjin, Wuhan, Xi'an, Zhengzhou
- Not yet recruitingBenmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
- Phase
- Phase 4
- Started
- 2025-04
- Posted
- Registry
- NCT06931145
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- Not yet recruitingNeoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT06998719
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingEfficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07004712
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingA Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07083375
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingA Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07086326
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Shanghai, Xi'an
- Not yet recruitingNovel Thin Bronchoscope Versus Ultrathin Bronchoscope for the Diagnosis of Peripheral Pulmonary Nodules
- Phase
- N/A
- Started
- 2025-09
- Posted
- Registry
- NCT07135297
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest Hospital; 4 listed hospitals as study sitesBeijing, Nanjing, Ningbo, Shanghai, Zhengzhou
- Not yet recruitingHigh-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07182708
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingAdebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07200154
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingA Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07200947
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingPhase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07242274
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingA Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06254599
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingA Multicenter Randomized Controlled Study of Interventional Treatment for Operable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer With Potential Recurrence as Minimal Residual Disease(MRD) Positive
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06524518
Age 18 years to 80 years (registered criteria)
Led by Xuanwu HospitalBeijing
- Not yet recruitingAumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06752408
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- Not yet recruitingYK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
- Phase
- Phase 3
- Started
- 2023-05
- Posted
- Registry
- NCT05767892
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
- Not yet recruitingSingle Ultra-high Dose Stereotactic Body Radiation Therapy for Early Lung Cancer
- Phase
- N/A
- Started
- 2023-06
- Posted
- Registry
- NCT05802654
Age 18 years to 80 years (registered criteria)
Led by Peking University Third HospitalBeijing
- Not yet recruitingA Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT05990127
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luoyang, Nanchang, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou
- Not yet recruitingA Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.
- Phase
- Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06142617
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- Not yet recruitingThe ctDNA for Evaluating Whether to Use Adjuvant Therapy After SBRT in Patients With Early Lung Cancer
- Phase
- N/A
- Started
- 2022-06
- Posted
- Registry
- NCT05411809
Age 18 years to 80 years (registered criteria)
Led by Peking University Third HospitalBeijing
- Enrolling by invitationComparison of the Effect of Surgical Resection Based on Lesion Extent Before and After Neoadjuvant Therapy in Patients With Stage II-IIIB Non-Small Cell Lung Cancer: A Single-Center, Real-World, Open-Label Study
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07373899
Age not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Enrolling by invitationRetrospective Multicenter Study of Patient-level T1CE/FLAIR MRI Deep Learning to Predict EGFR/ALK Driver Status in NSCLC Brain Metastases With External Validation and Survival Analysis
- Phase
- Not given
- Started
- 2025-11
- Posted
- Registry
- NCT07373951
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Enrolling by invitationSpontaneous Breathing Mode: A Risk for Hypoxemia During OLV?
- Phase
- Not given
- Started
- 2025-07
- Posted
- Registry
- NCT07494006
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- Enrolling by invitationLORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer
- Phase
- Not given
- Started
- 2024-10
- Posted
- Registry
- NCT06876675
Age 18 years to 80 years (registered criteria)
Led by Peking University Third HospitalBeijing
- Enrolling by invitation⁶⁸Ga-DPA in the Lung Cancer Diagnosis
- Phase
- Early phase 1
- Started
- 2024-09
- Posted
- Registry
- NCT07023068
Age 18 years to 85 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- Enrolling by invitationApplication of Generative Artificial Intelligence in Perioperative Personalized Rehabilitation for Older Adults With Lung Cancer
- Phase
- N/A
- Started
- 2024-10
- Posted
- Registry
- NCT07915193
Age 65 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Enrolling by invitationEfficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
- Phase
- Phase 3
- Started
- 2021-08
- Posted
- Registry
- NCT04762459
Age 18 years to 130 years (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Kunming, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou
- Enrolling by invitationFHND9041 Versus Afatinib for Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2021-08
- Posted
- Registry
- NCT06759857
Age 18 months to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Beijing
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Lung cancer | Pancreatic cancer | Breast cancer | Glioma | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Lymphoma | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Coronary heart disease | Congenital heart disease | Scoliosis | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| Aerospace Center Hospital航天中心医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | 1 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | 3 | 2 | none | 0 | none | none | none | none | none | none | 1 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Air Force General Hospital中国人民解放军空军特色医学中心 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing An Hospital | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 01 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Anding Hospital首都医科大学附属北京安定医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Anzhen Hospital首都医科大学附属北京安贞医院 | none | 6 | none | none | none | none | none | none | none | none | none | 1 | 0 | none | none | none | none | none | 2 | none | 0 | none | none | none | none | none | 0 | none | none | none | none | 19611 open | 805 open | none | none | 30 | none | 1 | none | none | none | 0 | none | none | 2 | 1 | 3 | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | |
| Beijing Army General Hospital中国人民解放军总医院第七医学中心 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Boren Hospital北京高博博仁医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | 1 | none | none | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Chao-Yang Hospital首都医科大学附属北京朝阳医院 | none | 8 | 18 | 12 | 662 open | 18 | 21 | none | none | none | 2 | 6 | 0 | 1 | 2 | 52 | none | none | none | 2 | 0 | none | 0 | 0 | none | none | none | none | none | none | none | 342 open | 3 | 40 | none | 3 | none | 13 | none | 1 | none | none | none | none | 1 | none | 4 | none | none | none | 3 | 2 | 1 | none | none | none | 0 | none | none | none | none | |
| Beijing Chest Hospital首都医科大学附属北京胸科医院 | none | none | none | none | 802 open | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Children's Hospital首都医科大学附属北京儿童医院 | none | none | none | none | none | none | none | none | 4 | 6 | none | 5 | none | 331 open | 4 | none | 4 | 9 | 311 open | 25 | 1 | 33 | 2 | 0 | 1 | 2 | none | none | 2 | none | 15 | 6 | 24 | 17 | 4 | 3 | none | none | none | 1 | 0 | 0 | none | 1 | 1 | 1 | 7 | 0 | none | none | none | none | none | 13 | 1 | none | none | none | 0 | none | none | |
| Beijing Daxing District People's Hospital北京市大兴区人民医院 | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Ditan Hospital, Capital Medical University首都医科大学附属北京地坛医院 | none | none | 72 | none | none | none | none | 5 | 0 | none | none | none | none | none | none | none | none | none | none | 7 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | 11 | 0 | none | none | none | none | none | none | none | none | none | |
| Beijing Friendship Hospital首都医科大学附属北京友谊医院 | none | 12 | 511 open | 457 open | 38 | 10 | 401 open | none | 1 | 1 | none | 2 | 2 | 47 | 1 | 1 | none | none | 523 open | 30 | none | 0 | none | 0 | none | none | 12 | 1 | none | 41 open | 4 | 251 open | 0 | none | none | 2 | none | 1 | none | none | none | none | 1 | none | 1 | none | 0 | 2 | none | none | 121 open | 4 | none | 0 | none | none | none | none | none | none | none | |
| Beijing Fuwai Hospital | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing GoBroad Hospital北京高博医院 | none | 01 open | 01 open | none | none | none | 01 open | none | none | none | none | none | none | none | none | 02 open | 04 open | none | none | 25 open | none | none | none | none | none | none | 01 open | 01 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Haidian Hospital北京市海淀医院 | none | none | none | none | 02 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Hospital北京医院 | none | none | 151 open | 4 | 74 | 10 | 25 | none | none | none | none | none | 0 | 1 | none | 2 | none | none | none | 6 | none | 2 | none | 0 | none | 0 | none | 11 | 41 open | none | none | 303 open | 3 | none | 0 | 1 | none | 8 | none | none | none | none | none | 0 | 2 | none | 1 | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | |
| Beijing Hospital, Capital Medical University北京市中西医结合医院 | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 4 | none | none | none | none | none | none | none | none | 4 | none | none | none | 1 | 1 | none | none | none | none | none | none | none | none | none | |
| Beijing Huairou Hospital北京怀柔医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing HuiLongGuan Hospital北京回龙观医院 | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Jishuitan Hospital北京积水潭医院 | none | none | none | none | none | none | none | none | none | none | 0 | 21 | none | none | 1 | 6 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 4 | none | 0 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Jishuitan Hospital Guizhou Hospital北京积水潭医院贵州医院 | none | none | none | none | none | none | none | none | none | none | 1 | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Jishuitan Hospital Liaocheng Hospital北京积水潭医院聊城医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Lu Daopei Hospital北京道培医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | 1 | none | 1 | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Luhe Hospital首都医科大学附属北京潞河医院 | none | none | none | none | none | 7 | none | none | none | 1 | none | 0 | 0 | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | |
| Beijing Rehabilitation Hospital首都医科大学附属北京康复医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Sanbo Brain Hospital北京三博脑科医院 | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Shijitan Hospital北京世纪坛医院 | none | 1 | 9 | 14 | 47 | none | 28 | 13 | 0 | none | none | 1 | none | 0 | none | none | none | none | none | 4 | 0 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | 1 | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Stomatological Hospital首都医科大学附属北京口腔医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 5 | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Tiantan Hospital首都医科大学附属北京天坛医院 | none | none | none | none | 18 | none | none | 30712 open | none | none | 14 | 0 | none | 0 | none | none | none | none | none | 242 open | none | 1 | none | none | none | 342 open | none | 1 | 609 open | none | none | 172 open | none | none | 6 | 1 | none | 2 | none | 4 | 0 | none | none | 1 | none | none | none | none | 0 | none | none | none | none | none | none | none | none | 1 | none | none | none | |
| Beijing Tongren Hospital首都医科大学附属北京同仁医院 | 6 | 1 | 30 | 15 | 34 | 8 | 14 | none | 8 | 21 | none | 7 | none | 9 | 1 | 6 | 01 open | none | 11 open | 357 open | none | 0 | none | none | none | 7 | 3 | 6 | none | 3 | none | 4 | 5 | 2 | 42 open | none | none | 1 | none | none | none | none | none | none | 1 | none | 2 | none | none | none | 2 | none | none | 1 | none | 0 | none | 4 | none | none | none | |
| Beijing Tsinghua Changgung Hospital北京清华长庚医院 | none | none | 29 | none | none | 4 | none | 12 | 1 | 0 | 0 | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 8 | none | none | 0 | 1 | 0 | none | 1 | none | 0 | none | none | none | 1 | 0 | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | |
| Beijing United Family Hospital北京和睦家医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | |
| Beijing Youan Hospital, Capital Medical University首都医科大学附属北京佑安医院 | none | none | 67 | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | 2 | 6 | none | none | none | none | none | none | none | none | none | 5 | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | 7 | 0 | none | none | none | none | none | none | none | none | none | |
| Beijng Anzhen Hospital | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College中国医学科学院肿瘤医院 | none | none | none | none | 9 | none | 4 | none | none | none | none | none | none | none | none | none | none | none | none | 01 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Capital Medical University Electric Teaching Hospital北京电力医院 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Capital Medical University Sanbo Brain Hospital北京三博脑科医院 | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Children's Hospital, Peking Union Medical College首都医科大学附属首都儿童医学中心 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | 2 | none | none | none | none | 2 | none | none | none | none | 0 | none | none | none | 1 | none | none | none | none | none | none | none | 2 | 3 | none | none | none | none | none | none | none | |
| China-Japan Friendship Hospital中日友好医院 | none | 5 | none | 13 | 563 open | 9 | none | none | none | none | none | 2 | none | none | none | 2 | none | none | 2 | 2 | none | none | none | none | none | 6 | 0 | none | none | none | none | 262 open | none | none | 0 | 01 open | none | 19 | 0 | none | 1 | 1 | 0 | 0 | none | none | 9 | none | none | none | 1 | 0 | none | none | none | none | 0 | none | none | none | none | |
| Chinese Medicine Affiliated Shenzhen Hospital北京中医药大学深圳医院(龙岗) | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Chinese Medicine Third Affiliated Hospital北京中医药大学第三附属医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Chinese PLA General Hospital中国人民解放军总医院 | 8 | 27 | 1846 open | 1406 open | 176 | 712 open | 914 open | 561 open | 3 | 2 | none | 12 | 7 | 1 | 1 | 52 open | 06 open | 11 open | 21 open | 3730 open | 0 | 1 | 1 | none | none | 122 open | 52 open | 4 | 461 open | none | none | 765 open | 9 | 11 | 0 | 0 | 2 | 3 | 1 | 20 | 2 | 3 | 1 | 6 | 0 | 1 | 171 open | 1 | none | 0 | 2 | none | none | none | none | none | 0 | 1 | none | none | none | |
| Civil Aviation General Hospital民航总医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Dongfang Hospital北京中医药大学东方医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 5 | none | none | none | 1 | none | 5 | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Dongzhimen Hospital北京中医药大学东直门医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 7 | none | none | none | none | none | 2 | none | 5 | none | none | none | none | none | 1 | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Dongzhimen Hospital北京中医药大学东直门医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Fangshan Hospital, Beijing University of Chinese Medicine北京市房山区中医医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital of Jinzhou Medical University锦州医科大学附属第一医院 | none | 3 | none | 19 | 32 | none | 21 | 8 | none | none | none | 5 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Hospital of Tsinghua University北京华信医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 10 | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Integrative Hospital | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Fu Wai Hospital中国医学科学院阜外心血管病医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 34 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Fu Wai Hospital中国医学科学院阜外心血管病医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 21 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Fu Wai Hospital, Peking Union Medical College中国医学科学院阜外心血管病医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Fuwai Hospital中国医学科学院阜外心血管病医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | 1 | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | 2432 open | 1503 open | none | none | 14 | none | none | none | none | none | 21 open | none | none | 5 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| FuWai Hospital, Peking Union Medical College | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Fuxing Hospital首都医科大学附属复兴医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| Guang Anmen Hospital中国中医科学院广安门医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guang'anmen Hospital中国中医科学院广安门医院 | none | none | none | 91 open | 321 open | 10 | 122 open | none | none | none | none | none | 1 | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | 3 | none | none | none | 20 | none | 2 | none | none | none | 1 | none | none | none | none | none | none | none | none | 5 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Medical Sciences Fuwai Hospital中国医学科学院阜外医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| National Cancer Center / Cancer Hospital, CAMS中国医学科学院肿瘤医院 | 331 open | 18410 open | 1033 open | 1312 open | 58725 open | 452 open | 33335 open | 101 open | none | none | none | 8 | 1 | 2 | 1 | none | none | 3 | none | 832 open | 1 | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Peking Union Medical College Fuwai Hospital | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Peking Union Medical College Hospital北京协和医院 | 3 | 41 open | 6510 open | 54 | 21313 open | 2279 open | 10610 open | 521 open | none | 0 | none | 4 | 6 | 71 open | 1 | 272 open | 1 | 161 open | 7 | 7410 open | 1 | 17 | 1 | 1 | none | 8 | 477 open | 6 | 9 | none | none | 294 open | 16 | 892 open | 3 | 27 | 0 | 18 | 14 | 44 | 31 open | 2 | 1 | 2 | 492 open | none | 5 | 1 | none | 14 | 221 open | 3 | 2 | 1 | 1 | 10 | none | none | 0 | none | none | |
| Peking University Aerospace Center Hospital | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Peking University Cancer Hospital北京大学肿瘤医院 | 2 | 826 open | 425 open | 2239 open | 16122 open | 342 open | 11614 open | none | none | none | none | 4 | 121 open | 1 | 2 | 3 | none | none | none | 834 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Peking University First Hospital北京大学第一医院 | none | none | 202 open | 271 open | 535 open | 283 open | 444 open | none | 0 | none | none | 41 open | 2 | 6 | 1 | 175 open | none | none | 1 | 366 open | none | 1 | 2 | none | none | 1 | 5 | 3 | none | none | none | 232 open | 5 | 71 open | 1 | 1 | 1 | 4 | none | 2 | 1 | 8 | 1 | 11 | 2 | 8 | 651 open | none | 0 | none | 0 | 1 | none | 1 | 5 | none | 1 | none | none | none | none | |
| Peking University International Hospital北大国际医院 | none | none | none | none | none | none | none | none | 1 | none | none | 0 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 6 | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | 2 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Peking University People's Hospital北京大学人民医院 | none | 2 | 241 open | 213 open | 10214 open | 31 open | 4422 open | none | none | 0 | 6 | 442 open | 102 open | none | 82 open | 195 open | 194 open | 293 open | 71 open | 146 open | none | 01 open | none | 42 open | 2 | 01 open | 121 open | 3 | none | none | none | 13 | 5 | 7 | none | 1 | none | 3 | none | none | none | none | none | none | 51 open | none | 0 | 0 | none | 2 | 7 | 0 | 0 | none | none | none | 0 | none | none | none | none | |
| Peking University Shougang Hospital北京大学首钢医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | 1 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | 0 | none | none | none | none | none | none | 0 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Peking University Third Hospital北京大学第三医院 | none | none | 121 open | 262 open | 514 open | 162 open | 282 open | 232 open | none | none | 6 | 7 | 2 | 0 | 0 | 7 | 0 | none | none | 313 open | 0 | 1 | none | 0 | none | 2 | 2 | none | 2 | none | none | 172 open | 5 | 41 | none | 1 | 0 | 2 | none | 522 open | 01 open | 1 | none | 1 | 0 | none | 1 | none | none | none | 0 | none | none | none | none | none | 0 | none | none | none | none | |
| Plastic Surgery Hospital中国医学科学院整形外科医院 | none | none | none | none | none | none | 20 | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Plastic Surgery Hospital, Peking Union Medical College | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| PUMC Hospital中国医学科学院北京协和医院 | none | none | none | none | none | 0 | none | none | none | none | none | 0 | 0 | none | 0 | none | none | 0 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | 0 | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | |
| Sanbo Brain Hospital首都医科大学三博脑科医院 | none | none | none | none | none | none | none | 301 open | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Sanbo Brain Hospital, Capital Medical University | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Second Artillery General Hospital中国人民解放军火箭军特色医学中心 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shijitan Hospital, Captial Medical University首都医科大学附属北京世纪坛医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wangjing Hospital中国中医科学院望京医院 | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Xiyuan Hospital中国中医科学院西苑医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | 25 | none | none | none | none | none | 0 | none | 1 | none | none | none | none | none | none | 9 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Xuanwu Hospital首都医科大学宣武医院 | 2 | none | 15 | 5 | 262 open | 6 | 12 | 25 | none | 0 | 7 | 1 | none | 3 | none | none | 0 | none | none | 7 | 1 | none | none | 1 | none | 52 open | 2 | 161 open | 7 | none | none | 151 open | 5 | 122 open | 9 | 6 | none | none | none | 7 | none | none | none | 1 | 0 | none | 2 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | |
| Yuquan Hospital清华大学玉泉医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Beijing.
- Oesophageal squamous cell carcinoma 6
- Osteosarcoma 1
- Gastrointestinal stromal tumour 0
- Haemophagocytic lymphohistiocytosis 2
- Beta thalassaemia 0
- IgG4-related disease 0
- Coronary heart disease 19611 open
- Congenital heart disease 805 open
- Takayasu arteritis 30
- Idiopathic pulmonary fibrosis 1
- Fabry disease 0
- Behçet disease 2
- Alport syndrome 1
- IgA nephropathy 3
- Primary biliary cholangitis 1
- Oesophageal squamous cell carcinoma 8
- Hepatocellular carcinoma 18
- Stomach cancer 12
- Lung cancer 662 open
- Pancreatic cancer 18
- Breast cancer 21
- Chordoma 2
- Osteosarcoma 6
- Gastrointestinal stromal tumour 0
- Neuroblastoma 1
- Ewing sarcoma 2
- Multiple myeloma 52
- Lymphoma 2
- Beta thalassaemia 0
- Atypical haemolytic uraemic syndrome 0
- Thrombotic thrombocytopenic purpura 0
- Coronary heart disease 342 open
- Congenital heart disease 3
- Scoliosis 40
- Takayasu arteritis 3
- Idiopathic pulmonary fibrosis 13
- Amyotrophic lateral sclerosis 1
- Behçet disease 1
- IgA nephropathy 4
- Primary biliary cholangitis 3
- Primary sclerosing cholangitis 2
- Congenital diaphragmatic hernia 1
- Familial adenomatous polyposis 0
- Hepatoblastoma 4
- Retinoblastoma 6
- Osteosarcoma 5
- Neuroblastoma 331 open
- Ewing sarcoma 4
- B-cell acute lymphoblastic leukaemia 4
- Aplastic anaemia 9
- Haemophagocytic lymphohistiocytosis 311 open
- Lymphoma 25
- Beta thalassaemia 1
- Haemophilia A 33
- Atypical haemolytic uraemic syndrome 2
- Thrombotic thrombocytopenic purpura 0
- Fanconi anaemia 1
- Neuromyelitis optica spectrum disorder 2
- Moyamoya disease 2
- Biliary atresia 15
- Coronary heart disease 6
- Congenital heart disease 24
- Scoliosis 17
- Anti-NMDA receptor encephalitis 4
- Takayasu arteritis 3
- Amyotrophic lateral sclerosis 1
- Spinal muscular atrophy 0
- Fabry disease 0
- Duchenne muscular dystrophy 1
- Behçet disease 1
- Alport syndrome 1
- IgA nephropathy 7
- Gaucher disease 0
- Hirschsprung disease 13
- Inherited epidermolysis bullosa 1
- Majeed syndrome 0
- Oesophageal squamous cell carcinoma 12
- Hepatocellular carcinoma 511 open
- Stomach cancer 457 open
- Lung cancer 38
- Pancreatic cancer 10
- Breast cancer 401 open
- Hepatoblastoma 1
- Retinoblastoma 1
- Osteosarcoma 2
- Gastrointestinal stromal tumour 2
- Neuroblastoma 47
- Ewing sarcoma 1
- Multiple myeloma 1
- Haemophagocytic lymphohistiocytosis 523 open
- Lymphoma 30
- Haemophilia A 0
- Thrombotic thrombocytopenic purpura 0
- IgG4-related disease 12
- Myasthenia gravis 1
- Wilson disease 41 open
- Biliary atresia 4
- Coronary heart disease 251 open
- Congenital heart disease 0
- Takayasu arteritis 2
- Idiopathic pulmonary fibrosis 1
- Pompe disease 1
- Behçet disease 1
- IgA nephropathy 0
- Gaucher disease 2
- Primary biliary cholangitis 121 open
- Primary sclerosing cholangitis 4
- Hirschsprung disease 0
- Hepatocellular carcinoma 151 open
- Stomach cancer 4
- Lung cancer 74
- Pancreatic cancer 10
- Breast cancer 25
- Gastrointestinal stromal tumour 0
- Neuroblastoma 1
- Multiple myeloma 2
- Lymphoma 6
- Haemophilia A 2
- Thrombotic thrombocytopenic purpura 0
- Neuromyelitis optica spectrum disorder 0
- Myasthenia gravis 11
- Moyamoya disease 41 open
- Coronary heart disease 303 open
- Congenital heart disease 3
- Anti-NMDA receptor encephalitis 0
- Takayasu arteritis 1
- Idiopathic pulmonary fibrosis 8
- Duchenne muscular dystrophy 0
- Behçet disease 2
- IgA nephropathy 1
- Inherited epidermolysis bullosa 0
- Lung cancer 18
- Glioma 30712 open
- Chordoma 14
- Osteosarcoma 0
- Neuroblastoma 0
- Lymphoma 242 open
- Haemophilia A 1
- Neuromyelitis optica spectrum disorder 342 open
- Myasthenia gravis 1
- Moyamoya disease 609 open
- Coronary heart disease 172 open
- Anti-NMDA receptor encephalitis 6
- Takayasu arteritis 1
- Idiopathic pulmonary fibrosis 2
- Amyotrophic lateral sclerosis 4
- Spinal muscular atrophy 0
- Duchenne muscular dystrophy 1
- Niemann–Pick disease type C 0
- Leber hereditary optic neuropathy 1
- Nasopharyngeal carcinoma 6
- Oesophageal squamous cell carcinoma 1
- Hepatocellular carcinoma 30
- Stomach cancer 15
- Lung cancer 34
- Pancreatic cancer 8
- Breast cancer 14
- Hepatoblastoma 8
- Retinoblastoma 21
- Osteosarcoma 7
- Neuroblastoma 9
- Ewing sarcoma 1
- Multiple myeloma 6
- B-cell acute lymphoblastic leukaemia 01 open
- Haemophagocytic lymphohistiocytosis 11 open
- Lymphoma 357 open
- Haemophilia A 0
- Neuromyelitis optica spectrum disorder 7
- IgG4-related disease 3
- Myasthenia gravis 6
- Wilson disease 3
- Coronary heart disease 4
- Congenital heart disease 5
- Scoliosis 2
- Anti-NMDA receptor encephalitis 42 open
- Idiopathic pulmonary fibrosis 1
- Behçet disease 1
- IgA nephropathy 2
- Primary biliary cholangitis 2
- Hirschsprung disease 1
- Hereditary angioedema 0
- Leber hereditary optic neuropathy 4
- Hepatocellular carcinoma 29
- Pancreatic cancer 4
- Glioma 12
- Hepatoblastoma 1
- Retinoblastoma 0
- Chordoma 0
- Osteosarcoma 2
- Congenital heart disease 8
- Takayasu arteritis 0
- Hepatic echinococcosis 1
- Idiopathic pulmonary fibrosis 0
- Amyotrophic lateral sclerosis 1
- Fabry disease 0
- Alport syndrome 1
- IgA nephropathy 0
- Primary sclerosing cholangitis 1
- Oesophageal squamous cell carcinoma 5
- Stomach cancer 13
- Lung cancer 563 open
- Pancreatic cancer 9
- Osteosarcoma 2
- Multiple myeloma 2
- Haemophagocytic lymphohistiocytosis 2
- Lymphoma 2
- Neuromyelitis optica spectrum disorder 6
- IgG4-related disease 0
- Coronary heart disease 262 open
- Anti-NMDA receptor encephalitis 0
- Takayasu arteritis 01 open
- Idiopathic pulmonary fibrosis 19
- Lymphangioleiomyomatosis 0
- Spinal muscular atrophy 1
- Fabry disease 1
- Pompe disease 0
- Duchenne muscular dystrophy 0
- IgA nephropathy 9
- Primary biliary cholangitis 1
- Primary sclerosing cholangitis 0
- Familial adenomatous polyposis 0
- Nasopharyngeal carcinoma 8
- Oesophageal squamous cell carcinoma 27
- Hepatocellular carcinoma 1846 open
- Stomach cancer 1406 open
- Lung cancer 176
- Pancreatic cancer 712 open
- Breast cancer 914 open
- Glioma 561 open
- Hepatoblastoma 3
- Retinoblastoma 2
- Osteosarcoma 12
- Gastrointestinal stromal tumour 7
- Neuroblastoma 1
- Ewing sarcoma 1
- Multiple myeloma 52 open
- B-cell acute lymphoblastic leukaemia 06 open
- Aplastic anaemia 11 open
- Haemophagocytic lymphohistiocytosis 21 open
- Lymphoma 3730 open
- Beta thalassaemia 0
- Haemophilia A 1
- Atypical haemolytic uraemic syndrome 1
- Neuromyelitis optica spectrum disorder 122 open
- IgG4-related disease 52 open
- Myasthenia gravis 4
- Moyamoya disease 461 open
- Coronary heart disease 765 open
- Congenital heart disease 9
- Scoliosis 11
- Anti-NMDA receptor encephalitis 0
- Takayasu arteritis 0
- Hepatic echinococcosis 2
- Idiopathic pulmonary fibrosis 3
- Lymphangioleiomyomatosis 1
- Amyotrophic lateral sclerosis 20
- Spinal muscular atrophy 2
- Fabry disease 3
- Pompe disease 1
- Duchenne muscular dystrophy 6
- Behçet disease 0
- Alport syndrome 1
- IgA nephropathy 171 open
- Gaucher disease 1
- Osteogenesis imperfecta 0
- Primary biliary cholangitis 2
- Familial adenomatous polyposis 0
- Leber hereditary optic neuropathy 1
- Nasopharyngeal carcinoma 331 open
- Oesophageal squamous cell carcinoma 18410 open
- Hepatocellular carcinoma 1033 open
- Stomach cancer 1312 open
- Lung cancer 58725 open
- Pancreatic cancer 452 open
- Breast cancer 33335 open
- Glioma 101 open
- Osteosarcoma 8
- Gastrointestinal stromal tumour 1
- Neuroblastoma 2
- Ewing sarcoma 1
- Aplastic anaemia 3
- Lymphoma 832 open
- Beta thalassaemia 1
- Fanconi anaemia 1
- Idiopathic pulmonary fibrosis 1
- Nasopharyngeal carcinoma 3
- Oesophageal squamous cell carcinoma 41 open
- Hepatocellular carcinoma 6510 open
- Stomach cancer 54
- Lung cancer 21313 open
- Pancreatic cancer 2279 open
- Breast cancer 10610 open
- Glioma 521 open
- Retinoblastoma 0
- Osteosarcoma 4
- Gastrointestinal stromal tumour 6
- Neuroblastoma 71 open
- Ewing sarcoma 1
- Multiple myeloma 272 open
- B-cell acute lymphoblastic leukaemia 1
- Aplastic anaemia 161 open
- Haemophagocytic lymphohistiocytosis 7
- Lymphoma 7410 open
- Beta thalassaemia 1
- Haemophilia A 17
- Atypical haemolytic uraemic syndrome 1
- Thrombotic thrombocytopenic purpura 1
- Neuromyelitis optica spectrum disorder 8
- IgG4-related disease 477 open
- Myasthenia gravis 6
- Moyamoya disease 9
- Coronary heart disease 294 open
- Congenital heart disease 16
- Scoliosis 892 open
- Anti-NMDA receptor encephalitis 3
- Takayasu arteritis 27
- Hepatic echinococcosis 0
- Idiopathic pulmonary fibrosis 18
- Lymphangioleiomyomatosis 14
- Amyotrophic lateral sclerosis 44
- Spinal muscular atrophy 31 open
- Fabry disease 2
- Pompe disease 1
- Duchenne muscular dystrophy 2
- Behçet disease 492 open
- IgA nephropathy 5
- Gaucher disease 1
- Osteogenesis imperfecta 14
- Primary biliary cholangitis 221 open
- Primary sclerosing cholangitis 3
- Congenital diaphragmatic hernia 2
- Hirschsprung disease 1
- Inherited epidermolysis bullosa 1
- Hereditary angioedema 10
- Majeed syndrome 0
- Nasopharyngeal carcinoma 2
- Oesophageal squamous cell carcinoma 826 open
- Hepatocellular carcinoma 425 open
- Stomach cancer 2239 open
- Lung cancer 16122 open
- Pancreatic cancer 342 open
- Breast cancer 11614 open
- Osteosarcoma 4
- Gastrointestinal stromal tumour 121 open
- Neuroblastoma 1
- Ewing sarcoma 2
- Multiple myeloma 3
- Lymphoma 834 open
- Anti-NMDA receptor encephalitis 0
- Hepatocellular carcinoma 202 open
- Stomach cancer 271 open
- Lung cancer 535 open
- Pancreatic cancer 283 open
- Breast cancer 444 open
- Hepatoblastoma 0
- Osteosarcoma 41 open
- Gastrointestinal stromal tumour 2
- Neuroblastoma 6
- Ewing sarcoma 1
- Multiple myeloma 175 open
- Haemophagocytic lymphohistiocytosis 1
- Lymphoma 366 open
- Haemophilia A 1
- Atypical haemolytic uraemic syndrome 2
- Neuromyelitis optica spectrum disorder 1
- IgG4-related disease 5
- Myasthenia gravis 3
- Coronary heart disease 232 open
- Congenital heart disease 5
- Scoliosis 71 open
- Anti-NMDA receptor encephalitis 1
- Takayasu arteritis 1
- Hepatic echinococcosis 1
- Idiopathic pulmonary fibrosis 4
- Amyotrophic lateral sclerosis 2
- Spinal muscular atrophy 1
- Fabry disease 8
- Pompe disease 1
- Duchenne muscular dystrophy 11
- Behçet disease 2
- Alport syndrome 8
- IgA nephropathy 651 open
- Niemann–Pick disease type C 0
- Primary biliary cholangitis 0
- Primary sclerosing cholangitis 1
- Hirschsprung disease 1
- Inherited epidermolysis bullosa 5
- Familial adenomatous polyposis 1
- Oesophageal squamous cell carcinoma 2
- Hepatocellular carcinoma 241 open
- Stomach cancer 213 open
- Lung cancer 10214 open
- Pancreatic cancer 31 open
- Breast cancer 4422 open
- Retinoblastoma 0
- Chordoma 6
- Osteosarcoma 442 open
- Gastrointestinal stromal tumour 102 open
- Ewing sarcoma 82 open
- Multiple myeloma 195 open
- B-cell acute lymphoblastic leukaemia 194 open
- Aplastic anaemia 293 open
- Haemophagocytic lymphohistiocytosis 71 open
- Lymphoma 146 open
- Haemophilia A 01 open
- Thrombotic thrombocytopenic purpura 42 open
- Fanconi anaemia 2
- Neuromyelitis optica spectrum disorder 01 open
- IgG4-related disease 121 open
- Myasthenia gravis 3
- Coronary heart disease 13
- Congenital heart disease 5
- Scoliosis 7
- Takayasu arteritis 1
- Idiopathic pulmonary fibrosis 3
- Behçet disease 51 open
- IgA nephropathy 0
- Gaucher disease 0
- Osteogenesis imperfecta 2
- Primary biliary cholangitis 7
- Primary sclerosing cholangitis 0
- Congenital diaphragmatic hernia 0
- Familial adenomatous polyposis 0
- Hepatocellular carcinoma 121 open
- Stomach cancer 262 open
- Lung cancer 514 open
- Pancreatic cancer 162 open
- Breast cancer 282 open
- Glioma 232 open
- Chordoma 6
- Osteosarcoma 7
- Gastrointestinal stromal tumour 2
- Neuroblastoma 0
- Ewing sarcoma 0
- Multiple myeloma 7
- B-cell acute lymphoblastic leukaemia 0
- Lymphoma 313 open
- Beta thalassaemia 0
- Haemophilia A 1
- Thrombotic thrombocytopenic purpura 0
- Neuromyelitis optica spectrum disorder 2
- IgG4-related disease 2
- Moyamoya disease 2
- Coronary heart disease 172 open
- Congenital heart disease 5
- Scoliosis 41
- Takayasu arteritis 1
- Hepatic echinococcosis 0
- Idiopathic pulmonary fibrosis 2
- Amyotrophic lateral sclerosis 522 open
- Spinal muscular atrophy 01 open
- Fabry disease 1
- Duchenne muscular dystrophy 1
- Behçet disease 0
- IgA nephropathy 1
- Primary biliary cholangitis 0
- Familial adenomatous polyposis 0
- Nasopharyngeal carcinoma 2
- Hepatocellular carcinoma 15
- Stomach cancer 5
- Lung cancer 262 open
- Pancreatic cancer 6
- Breast cancer 12
- Glioma 25
- Retinoblastoma 0
- Chordoma 7
- Osteosarcoma 1
- Neuroblastoma 3
- B-cell acute lymphoblastic leukaemia 0
- Lymphoma 7
- Beta thalassaemia 1
- Thrombotic thrombocytopenic purpura 1
- Neuromyelitis optica spectrum disorder 52 open
- IgG4-related disease 2
- Myasthenia gravis 161 open
- Moyamoya disease 7
- Coronary heart disease 151 open
- Congenital heart disease 5
- Scoliosis 122 open
- Anti-NMDA receptor encephalitis 9
- Takayasu arteritis 6
- Amyotrophic lateral sclerosis 7
- Duchenne muscular dystrophy 1
- Behçet disease 0
- IgA nephropathy 2
- Niemann–Pick disease type C 1
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for lung cancer.
Counts are listed hospitals only, not every hospital in each city.
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Beijing on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.